Home > Publications Database > Phosphatidylethanolamines are the Main Lipid Class Altered in Red Blood Cells from Patients with VPS13A Disease/Chorea-Acanthocytosis. > print

001     277726
005     20250403095900.0
024 7 _ |a 10.1002/mds.30086
|2 doi
024 7 _ |a pmid:39665525
|2 pmid
024 7 _ |a pmc:PMC11926492
|2 pmc
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
037 _ _ |a DZNE-2025-00447
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Peikert, Kevin
|0 P:(DE-2719)9000983
|b 0
245 _ _ |a Phosphatidylethanolamines are the Main Lipid Class Altered in Red Blood Cells from Patients with VPS13A Disease/Chorea-Acanthocytosis.
260 _ _ |a New York, NY
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1743593170_4325
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a VPS13A disease is an ultra-rare disorder caused by loss of function mutations in VPS13A characterized by striatal degeneration and by red blood cell (RBC) acanthocytosis. VPS13A is a bridge-like protein mediating lipid transfer at membrane contact sites.To assess the lipid composition of patient-derived RBCs.RBCs collected from 5 VPS13A disease patients and 12 control subjects were analyzed by mass spectrometry (lipidomics).While we found no significant differences in the overall lipid class level, alterations in certain species were detected: phosphatidylethanolamine species with both longer chain length and higher unsaturation were increased in VPS13A disease samples. Specific ceramide, phosphatidylcholine, and sphingomyelin species were also altered.The presented alterations of particular lipid species in RBCs in VPS13A disease may contribute to (1) the understanding of acanthocyte formation, and (2) future biomarker identification. Lipid distribution seems to play a key role in the pathophysiology of VPS13A disease. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a VPS13A protein, human
|2 NLM Chemicals
650 _ 7 |a Phosphatidylethanolamines
|2 NLM Chemicals
650 _ 7 |a Vesicular Transport Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neuroacanthocytosis: genetics
|2 MeSH
650 _ 2 |a Neuroacanthocytosis: metabolism
|2 MeSH
650 _ 2 |a Neuroacanthocytosis: blood
|2 MeSH
650 _ 2 |a Neuroacanthocytosis: pathology
|2 MeSH
650 _ 2 |a Phosphatidylethanolamines: metabolism
|2 MeSH
650 _ 2 |a Erythrocytes: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Vesicular Transport Proteins: genetics
|2 MeSH
650 _ 2 |a Vesicular Transport Proteins: metabolism
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Lipidomics: methods
|2 MeSH
650 _ 2 |a Acanthocytes: metabolism
|2 MeSH
650 _ 2 |a Acanthocytes: pathology
|2 MeSH
700 1 _ |a Spranger, Adrian
|b 1
700 1 _ |a Miltenberger-Miltenyi, Gabriel
|0 0000-0003-0224-1281
|b 2
700 1 _ |a Glaß, Hannes
|b 3
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 4
|u dzne
700 1 _ |a Klose, Christian
|b 5
700 1 _ |a Tyteca, Donatienne
|b 6
700 1 _ |a Hermann, Andreas
|0 P:(DE-2719)2811732
|b 7
|e Last author
773 _ _ |a 10.1002/mds.30086
|g Vol. 40, no. 3, p. 544 - 549
|0 PERI:(DE-600)2041249-6
|n 3
|p 544 - 549
|t Movement disorders
|v 40
|y 2025
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.xlsx
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP3.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277726/files/DZNE-2025-00447.pdf
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.ods
856 4 _ |u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.xls
856 4 _ |x pdfa
|u https://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP3.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277726/files/DZNE-2025-00447.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277726
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2814178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1511100
|k AG Hermann
|l Translational Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1511100
980 _ _ |a I:(DE-2719)1710012
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21